Third Rock Ventures, a Boston venture firm focused on life sciences investments, has filed papers with the SEC to raise a second fund. The proposed amount of the new fund is $400 million, yet the paperwork indicates that none of those funds had been raised as of the April 9 filing. Still, this is good news for early-stage biotech startups, which have been the sweet spot for Third Rock’s maiden fund of $378 million, closed in 2007.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
